All Articles

TROP2-targeting antibody–drug conjugates in breast cancer and ovarian carcinoma: therapeutic advances and resistance mechanisms

Ivosidenib enhances cisplatin sensitivity in ovarian cancer by reducing cancer cell stemness

Ovarian tumor microenvironment contributes to tumor progression and chemoresistance

Unlocking the potential of immunotherapy in platinum-resistant ovarian cancer: rationale, challenges, and novel strategies

Novel players in the development of chemoresistance in ovarian cancer: ovarian cancer stem cells, non-coding RNA and nuclear receptors

A comprehensive overview of recent developments on the mechanisms and pathways of ferroptosis in cancer: the potential implications for therapeutic strategies in ovarian cancer

The clinical challenges of homologous recombination proficiency in ovarian cancer: from intrinsic resistance to new treatment opportunities

Immune checkpoint inhibitors in ovarian cancer: where do we go from here?

The evolving role of DNA damage response in overcoming therapeutic resistance in ovarian cancer

Ovarian cancer resistance to PARPi and platinum-containing chemotherapy

A patient with relapsed high-grade serous ovarian carcinoma with somatic RAD51C mutations treated with PARPi monotherapy: a case report

Ovarian cancer recurrence: “is the definition of platinum resistance modified by PARP inhibitors and other intervening treatments?”

Ovarian cancer recurrence: is the definition of platinum resistance modified by PARPi and other intervening treatments? The evolving landscape in the management of platinum-resistant ovarian cancer

Ovarian cancer recurrence: is the definition of platinum sensitivity modified by PARPi, bevacizumab or other intervening treatments? : a clinical perspective

Mechanisms of chemotherapy resistance in ovarian cancer

Tackling cisplatin resistance in ovarian cancer: what can we do?

History of intraperitoneal platinum drug delivery for ovarian cancer and its future applications

ABCA1 is associated with the development of acquired chemotherapy resistance and predicts poor ovarian cancer outcome